MeiraGTx Holdings plc announced that it will host a conference call and webcast to present an update on the Company's AAV-hAQP1 clinical program for the treatment of grade 2/3 radiation-induced xerostomia (RIX) on June 27, 2023, at 8:00 a.m. ET. The presentation will include: Data from the completed Phase 1 AQUAx clinical study for the 24 patients treated with AAV-hAQ P1 in the unilateral and bilateral cohorts:afety anand tolerability; 12-month data for PRO assessments of xerostomia symptoms in the bilateral cohorts (n=12); 12-month data for PRO assessment of xerostomia symptom in the bilateral cohorts (n<12); Change over time in the objective measure of saliva flow out to 12 months for both bilateral and unilateral cohorts; Long-term follow up data to 2 or 3 years for the participants who have reached those timepoints. Summaryry of biopsy data from a subset of patients in the Phase National Institutes of Health (NIH) study of AAV-hA QP1 in RIX demonstrating parotid transduction and durability out to at least 24-months post-treatment.

The Phase 1 AQUAx clinical trial is an open-label, non-randomized, dose escalation trial designed to evaluate the safety of MeiraGTx's investigational gene therapy AAV-hAQp1 when administered via Stensen's duct to one or both parotid gland in patients who have been diagnosed with grade 2 or 3 radiation-induced xerostOMia and who have remained cancer free for at least five years (or at least two years if HPV+) after receiving radiation treatment for head and neck cancer. Primary endpoint of the trial is safety, with efficacy endpoints including patient reported measures of xerostomia characteristics and the evaluation of the change in parotid gland salivary output after treatment with AAV-hA Q P1.